Development of Th17-Associated Interstitial Kidney Inflammation in Lupus-Prone Mice Lacking the Gene Encoding STAT-1

Arthritis and Rheumatology

Volumn 68, Issue 5, 2016, Pages 1233-1244

  Yiu, Gloria ^a   Rasmussen, Tue K ^a,b   Ajami, Bahareh ^a   Haddon, David J ^a   Chu, Alvina D ^a   Tangsombatvisit, Stephanie ^a   Haynes, Winston A ^a   Diep, Vivian ^a   Steinman, Larry ^a   Faix, James ^a   Utz, Paul J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR 9; ORPHAN NUCLEAR RECEPTOR; RETINOIC ACID RECEPTOR; STAT1 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; ALPHA BETA INTERFERON RECEPTOR; AUTOANTIBODY; IFNAR2 PROTEIN, MOUSE; IRF9 PROTEIN, MOUSE; STAT1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GLOMERULONEPHRITIS; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; KIDNEY; KNOCKOUT MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY; PROTEINURIA;

ANIMALS; ANTIBODY FORMATION; AUTOANTIBODIES; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULONEPHRITIS; INTERFERON TYPE I; INTERFERON-GAMMA; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; MICE, KNOCKOUT; NEPHRITIS, INTERSTITIAL; PROTEINURIA; RECEPTOR, INTERFERON ALPHA-BETA; STAT1 TRANSCRIPTION FACTOR; TH17 CELLS;

EID: 84964570069     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39535     Document Type: Article

References (52)

1. Xiong W, Lahita RG., Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol 2014; 10: 97-107.
2. Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, et al., Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013; 65: 1011-21.
3. Ronnblom LE, Alm GV, Oberg K., Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-α treatment. Acta Oncol 1991; 30: 537-40.
4. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al., Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-5.
5. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
6. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
7. Bauer JW, Baechler EC, Michelle Petri, Batliwalla FM, Crawford D, Ortmann WA, et al., Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: e491.
8. Lu Q, Shen N, Li XM, Chen SL., Genomic view of IFN-α response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immun 2007; 8: 590-603.
9. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al., Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777-88.
10. Braun D, Geraldes P, Demengeot J., Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003; 20: 15-25.
11. Hron JD, Peng SL., Type I IFN protects against murine lupus. J Immunol 2004; 173: 2134-42.
12. Thibault DL, Chu AD, Graham KL, Balboni I, Lee LY, Kohlmoos C, et al., IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest 2008; 118: 1417-26.
13. Thibault DL, Graham KL, Lee LY, Balboni I, Hertzog PJ, Utz PJ., Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res Ther 2009; 11: R112.
14. Ward MM, Pyun E, Studenski S., Causes of death in systemic lupus erythematosus: long-term followup of an inception cohort. Arthritis Rheum 1995; 38: 1492-9.
15. Theofilopoulos AN, Dixon FJ., Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269-390.
16. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M., Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179: 305-10.
17. Viallard JF, Pellegrin JL, Ranchin V, Schaeverbeke T, Dehais J, Longy-Boursier M, et al., Th1 (IL-2, interferon-gamma (IFN-γ)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999; 115: 189-95.
18. Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR., Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res (Hoboken) 2011; 63: 865-74.
19. Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JE,. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney International 1984; 25: 689-95.
20. Winfield JB, Faiferman I, Koffler D., Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus: association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977; 59: 90-6.
21. Pankewycz OG, Migliorini P, Madaio MP., Polyreactive autoantibodies are nephritogenic in murine lupus nephritis. J Immunol 1987; 139: 3287-94.
22. Hou LF, He SJ, Li X, Yang Y, He PL, Zhou Y, et al., Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum 2011; 63: 2445-55.
23. Chen DY, Chen YM, Wen MC, Hsieh TY, Hung WT, Lan JL., The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 2012; 21: 1385-96.
24. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW., Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 127: 385-93.
25. Dias PM, Banerjee G., The role of Th17/IL-17 on eosinophilic inflammation. J Autoimmun 2013; 40: 9-20.
26. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al., Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1472-83.
27. Kurts C, Panzer U, Anders HJ, Rees AJ., The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol 2013; 13: 738-53.
28. Liu CL, Tangsombatvisit S, Rosenberg JM, Mandelbaum G, Gillespie EC, Gozani OP, et al., Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Res Ther 2012; 14: R25.
29. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, et al., Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002; 8: 295-301.
30. Price JV, Tangsombatvisit S, Xu G, Yu J, Levy D, Baechler EC, et al., On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions. Nat Med 2012; 18: 1434-40.
31. Sekine H, Graham KL, Zhao S, Elliott MK, Ruiz P, Utz PJ, et al., Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus. J Immunol 2006; 177: 7423-34.
32. Tusher VG, Tibshirani R, Chu G., Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-21.
33. Cerutti A, Qiao X, He B., Plasmacytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching. Immunol Cell Biol 2005; 83: 554-62.
34. Lee BL, Moon JE, Shu JH, Yuan L, Newman ZR, Schekman R, et al., UNC93B1 mediates differential trafficking of endosomal TLRs. Elife 2013; 2: e00291.
35. Papin JA, Palsson BO., The JAK-STAT signaling network in the human B-cell: an extreme signaling pathway analysis. Biophys J 2004; 87: 37-46.
36. Lin JX, Migone TS, Tseng M, Friedmann M, Weatherbee JA, Zhou L, et al., The role of shared receptor motifs and common stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995; 2: 331-9.
37. Hale MB, Krutzik PO, Samra SS, Crane JM, Nolan GP., Stage dependent aberrant regulation of cytokine-STAT signaling in murine systemic lupus erythematosus. PLoS One 2009; 4: e6756.
38. Basu R, Hatton RD, Weaver CT., The Th17 family: flexibility follows function. Immunol Rev 2013; 252: 89-103.
39. Park MH, D'Agati V, Appel GB, Pirani CL., Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 1986; 44: 309-19.
40. Wehrmann M, Bohle A, Held H, Schumm G, Kendziorra H, Pressler H., Long-term prognosis of focal sclerosing glomerulonephritis: an analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990; 33: 115-22.
41. Bettelli E, Oukka M, Kuchroo VK., TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8: 345-50.
42. Wong CK, Ho CY, Li EK, Lam CW., Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9: 589-93.
43. Crispin JC, Oukka M, Bayliss G, Cohen RA, Beek CA, Stillman IE, et al., Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 181: 8761-6.
44. Wang Y, Ito S, Chino Y, Goto D, Matsumoto I, Murata H, et al., Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol 2010; 159: 1-10.
45. Liu J, Karypis G, Hippen KL, Vegoe AL, Ruiz P, Gilkeson GS, et al., Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun 2006; 7: 156-68.
46. lpr mice. J Immunol 998; 161: 494-503.
47. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, et al., Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 2011; 12: 247-54.
48. Matsumoto M, Tanaka N, Harada H, Kimura T, Yokochi T, Kitagawa M, et al., Activation of the transcription factor ISGF3 by interferon-γ. Biol Chem 1999; 380: 699-703.
49. Hall JC, Casciola-Rosen L, Berger AE, Kapsogeorgou EK, Cheadle C, Tzioufas AG, et al., Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A 2012; 109: 17609-14.
50. De Weerd NA, Vivian JP, Nguyen TK, Mangan NE, Gould JA, Braniff SJ, et al., Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1. Nat Immunol 2013; 14: 901-7.
51. Baccala R, Gonzalez-Quintial R, Schreiber RD, Lawson BR, Kono DH, Theofilopoulos AN., Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice. J Immunol 2012; 189: 5976-84.
52. Mangini AJ, Lafyatis R, Van Seventer JM., Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108: 11-23.